Overview
- Indomo, co-founded by Hims & Hers cofounder Jack Abraham, is developing ClearPen as a prescription intradermal auto-injector that delivers triamcinolone acetonide into inflamed acne lesions.
- The reusable device is designed with a short, hidden needle that auto-retracts and delivers a metered single-use dose at the press of a button.
- The company says Phase 2 clinical testing is planned for 2026, with a later Phase 3 and FDA review required, and no launch date or published safety or efficacy data yet.
- Indomo anticipates prescriptions through dermatologists and telehealth, expects pricing in line with in-office shots, and aims for potential insurance reimbursement.
- Dermatologists cited in the reporting warn that at-home corticosteroid injections carry risks including improper depth, skin depressions, and worsening infection, underscoring the need for clinician guidance.